See more : Pila Pharma AB (publ) (PILA.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Cosmo Bio Company,Limited (3386.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cosmo Bio Company,Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Dong Sung Bio Pharm.Co.,Ltd. (002210.KS) Income Statement Analysis – Financial Results
- Giga-tronics Incorporated (GIGA) Income Statement Analysis – Financial Results
- Polestar Automotive Holding UK PLC (PSNY) Income Statement Analysis – Financial Results
- Finning International Inc. (FTT.TO) Income Statement Analysis – Financial Results
- Diamines and Chemicals Limited (DIAMINESQ.BO) Income Statement Analysis – Financial Results
Cosmo Bio Company,Limited (3386.T)
About Cosmo Bio Company,Limited
Cosmo Bio Company,Limited engages in the import, export, manufacture, marketing, and sale of life science research biotools. Its life science research tools include reagents, kits, instruments, software, and diagnostics products. The company offers research reagents, such as antibodies, antigens, biologically active substances, enzymes, substrates, peptides, amino acids, chemicals, carbohydrates, lipids, virus components, bacteria, and others, as well as offers detection reagents, cell and tissue culture systems, gene analysis systems, and others. It also provides research instruments comprising electrophoresis apparatuses, cell culture labware, gene manipulation systems, data analysis software, and others; drug discovery and custom research services; and clinical diagnostics. In addition, the company develops and manufactures cell/cell culture products, including adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, mesenchymal stem, and feeder cells, as well as tumor cell lines, coating reagents, macrophage-related products, etc.; and assay kit related products that comprise various measurement kits, staining kits, detection/purification kits, etc. Further, it offers biotechnology research equipment, which include constant-temperature transport containers, aluminum block mat heat insulation devices, dew condensation prevention glass plates, etc.; and consigned, custom peptide synthesis, and antibody production services. The company serves laboratories, research institutes, and life-science education and testing organizations. It sells its products through outlets in Japan, as well as a network of sales agents internationally. Cosmo Bio Company,Limited was founded in 1978 and is headquartered in Tokyo, Japan.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 9.34B | 9.55B | 9.23B | 8.09B | 7.59B |
Cost of Revenue | 6.09B | 6.11B | 5.57B | 4.94B | 4.71B |
Gross Profit | 3.25B | 3.44B | 3.66B | 3.15B | 2.88B |
Gross Profit Ratio | 34.80% | 36.02% | 39.64% | 38.95% | 37.94% |
Research & Development | 73.00M | 82.00M | 70.00M | 80.00M | 81.00M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 2.73B | 2.62B | 2.61B | 2.40B | 2.47B |
Other Expenses | 0.00 | 6.00M | 25.00M | 32.00M | 0.00 |
Operating Expenses | 2.73B | 2.62B | 2.61B | 2.40B | 2.54B |
Cost & Expenses | 8.82B | 8.74B | 8.18B | 7.34B | 7.25B |
Interest Income | 6.00M | 3.00M | 3.00M | 2.00M | 2.00M |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 148.00M | 141.00M | 166.00M | 175.00M | 207.00M |
EBITDA | 799.00M | 958.00M | 1.22B | 928.00M | 613.00M |
EBITDA Ratio | 8.55% | 10.02% | 13.70% | 12.31% | 8.08% |
Operating Income | 519.00M | 816.00M | 1.05B | 752.00M | 406.00M |
Operating Income Ratio | 5.56% | 8.54% | 11.35% | 9.29% | 5.35% |
Total Other Income/Expenses | 134.00M | -26.00M | 51.00M | 256.00M | -18.00M |
Income Before Tax | 653.00M | 790.00M | 1.10B | 1.01B | 387.00M |
Income Before Tax Ratio | 6.99% | 8.27% | 11.91% | 12.46% | 5.10% |
Income Tax Expense | 191.00M | 238.00M | 330.00M | 307.00M | 142.00M |
Net Income | 442.00M | 517.00M | 737.00M | 674.00M | 237.00M |
Net Income Ratio | 4.73% | 5.41% | 7.98% | 8.33% | 3.12% |
EPS | 75.83 | 89.13 | 126.94 | 113.70 | 39.98 |
EPS Diluted | 75.83 | 89.13 | 126.94 | 113.70 | 39.98 |
Weighted Avg Shares Out | 5.83M | 5.81M | 5.81M | 5.93M | 5.93M |
Weighted Avg Shares Out (Dil) | 5.83M | 5.81M | 5.81M | 5.93M | 5.93M |
Source: https://incomestatements.info
Category: Stock Reports